Key Takeaways
- Tariffs on US drug imports still could be coming, but President Trump’s decision to pause tariffs with most global trade partners for 90 days suggests they will not be immediate.
- Uncertainty about pharma's position in the tariff debate remains.
- Trump continued to rail against US drug prices versus other countries, but a different issue could carry its own policy concerns for pharma.
The pharma industry has more to worry about from the Trump Administration despite the 9 April announcement of a 90-day pause for most tariffs except those in China and a...
The tariff saga has unfolded like a classic Trump presidency moment with initial chaos and disruption bumping against market realities and plateauing into a mix of relief and prolonged uncertainty....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?